BlackRock Inc. lifted its holdings in shares of Immune Design Corp (NASDAQ:IMDZ) by 10.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,121,271 shares of the biotechnology company’s stock after acquiring an additional 204,171 shares during the quarter. BlackRock Inc. owned 4.40% of Immune Design worth $9,651,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of IMDZ. Essex Investment Management Co. LLC bought a new position in Immune Design during the second quarter valued at $192,000. Alps Advisors Inc. bought a new position in Immune Design during the second quarter valued at $318,000. Finally, Dimensional Fund Advisors LP grew its holdings in Immune Design by 456.7% during the first quarter. Dimensional Fund Advisors LP now owns 192,330 shares of the biotechnology company’s stock valued at $635,000 after purchasing an additional 157,784 shares during the period. 49.33% of the stock is owned by institutional investors.
Immune Design stock opened at $1.57 on Monday. Immune Design Corp has a one year low of $1.29 and a one year high of $5.05. The firm has a market capitalization of $75.62 million, a PE ratio of -0.90 and a beta of 2.54.
Several equities analysts have weighed in on IMDZ shares. HC Wainwright started coverage on Immune Design in a report on Wednesday, August 29th. They set a “buy” rating and a $11.00 price objective for the company. Zacks Investment Research raised Immune Design from a “sell” rating to a “hold” rating in a report on Wednesday, October 3rd. Leerink Swann lowered Immune Design from an “outperform” rating to a “market perform” rating in a report on Friday, October 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Immune Design in a report on Friday, October 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $7.25.
About Immune Design
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Featured Article: Google Finance
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.